Skip to main content
Premium Trial:

Request an Annual Quote

BD Biosciences BD FACSArray and NanoMarkets The Impact of Nanotechnology in Drug Discovery: Global Developments, Market Analysis, and Future Prospects Report

Premium

BD Biosciences announced last week the availability of the BD FACSArray bioanalyzer, a platform for rapid high-content analysis of proteins in cell biology, immunology, and proteomics. The platform is capable of multiplexed bead-based and cellular assays, BD said.

BD Biosciences Clontech also announced last week the availability of the BD Living Colors AcGFP1, a fluorescent protein derived from the jellyfish Aequorea coerulescens. The company said that AcGFP is an alternative to enhanced GFP, which the company discontinued due to expiration of a product license. The product announcement comes on the heels of the company’s introduction of its dsRed-monomer (see Inside Bioassays, 2/1/2005). BD said that both new fluorescent proteins are ideal for multicolor applications in fluorescence microscopy and flow cytometry.


NanoMarkets has released a new report entitled “The Impact of Nanotechnology in Drug Discovery: Global Developments, Market Analysis, and Future Prospects.”

The 218-page report analyzes drivers, restraints, challenges, regulatory issues, and government funding policies that impact nano-scale drug discovery, and contains profiles of 30 companies active in this space, NanoMarkets said.

The report predicts that by 2009, 19 percent of nano-enabled drug discovery revenues will come from control and analysis of cells; 13 percent from DNA/RNA sizing, electrophoresis, and quantitation; 11 percent from genotyping; and 10 percent from high-throughput screening.

More information on the report can be found at http://www.nanomarkets.net/.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.